Maximizing function in Alzheimer's disease: What role for tacrine?

American Family Physician

Volumn 54, Issue 2, 1996, Pages 645-656

  Smucker, William D ^a  

^a NORTHEAST OHIO MEDICAL UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; TACRINE;

ALZHEIMER DISEASE; ARTICLE; CLINICAL TRIAL; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEGENERATIVE DISEASE; DISEASE SEVERITY; DRUG APPROVAL; DRUG EFFICACY; FOOD AND DRUG ADMINISTRATION; FUNCTIONAL ASSESSMENT; HUMAN; NEUROLOGIC DISEASE; TREATMENT OUTCOME;

ALZHEIMER DISEASE; ASPARTATE AMINOTRANSFERASES; CHOLINESTERASE INHIBITORS; COGNITION; HUMANS; LIVER FUNCTION TESTS; TACRINE; TREATMENT OUTCOME;

EID: 0029767409     PISSN: 0002838X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Evans DA, Funkenstein HH, Albert MS, Scherr PA, Cook NR, Chown MJ, et al. Prevalence of Alzheimer's disease in a community population of older persons. Higher than previously reported. JAMA 1989;262:2551-6.
2. Callahan CM, Hendrie HC, Tierney WM. Documentation and evaluation of cognitive impairment in elderly primary care patients. Ann Intern Med 1995;122:422-9.
3. Practice parameter for diagnosis and evaluation of dementia. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 1994;44:2203-6.
4. Clarfield AM. The reversible dementias: do they reverse? Ann Intern Med 1988;109:476-86.
5. Fleming KC, Adams AC, Petersen RC. Dementia: diagnosis and evaluation. Mayo Clin Proc 1995;70: 1093-107.
6. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, D.C.: American Psychiatric Association, 1994:142-3.
7. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state." A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-98.
8. Kukull WA, Larson EB, Teri L, Bowen J, McCormick W, Pfanschmidt ML. The Mini-Mental State Examination score and the clinical diagnosis of dementia. J Clin Epidemiol 1994;7:1061-7.
9. Larson EB, Reifler BV, Featherstone HJ, English DR. Dementia in elderly outpatients: a prospective study. Ann Intern Med 1984;100:417-23.
10. Overman W Jr, Stoudemire A. Guidelines for legal and financial counseling of Alzheimer's disease patients and their families. Am J Psychiatry 1988; 145:1495-500.
11. Robinson A, Spencer B, White L, eds. Understanding difficult behaviors: some practical suggestions for coping with Alzheimer's disease and related illnesses. Ypsilanti, Mich.: Geriatric Education Center of Michigan, 1989.
12. Gallo JJ, Franch MS, Reichel W. Dementing illness: the patient, caregiver and community. Am Fam Physician 1991;43:1669-75.
13. Patel SV. Pharmacotherapy of cognitive impairment in Alzheimer's disease: a review. J Geriatr Psychiatry Neurol 1995;8:81-95.
14. Wagstaff AJ, McTavish D. Tacrine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in Alzheimer's disease. Drugs Aging 1994;4:510-40 [Published erratum appears in Drugs Aging 1994;5:95].
15. Clipp EC, Moore MJ. Caregiver time use: an outcome measure in clinical trial research on Alzheimer's disease. Clin Pharmacol Ther 1995;58: 228-36.
16. Davis KL, Thai LJ, Gamzu ER, Davis CS, Woolson RF, Gracon SI, et al. A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. The Tacrine Collaborative Study Group. N Engl J Med 1992;327:1253-9.
17. Farlow M, Gracon SI, Hershey LA, Lewis KW, Sadowsky CH, Dolan-Ureno J. A controlled trial of tacrine in Alzheimer's disease. The Tacrine Study Group, JAMA 1992;268:2523-9.
18. Knapp MJ, Knopman DS, Solomon PR, Pendlebury WW, Davis CS, Gracon SI. A 30-week randomized Controlled trial of high-dose tacrine in patients with Alzheimer's disease. The Tacrine Study Group. JAMA 1994;271:985-91.
19. Knopman D, Schneider L, Davis K, Talwalker S, Smith F, Hoover T, et al. Long-term tacrine (Cognex) treatment: effects on nursing home placement and mortality. Neurology (In press).
20. Crismon ML. Tacrine: first drug approved for Alzheimer's disease. Ann Pharmacother 1994;28: 744-51.
21. Winker MA. Tacrine for Alzheimer's disease. Which patient what dose? [Editorial]. JAMA 1994;271:1023-4.
22. Hutton JT, Dippel RL, Loewenson RB, Mortimer JA, Christians BL. Predictors of nursing home placement of patients with Alzheimer's disease. Tex Med 1985;81:40-3.
23. Watkins PB, Zimmerman HJ; Knapp MJ, Gracon SI, Lewis KW. Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. JAMA 1994;271:992-8.
24. Manning FC. Tacrine therapy for the dementia of Alzheimer's disease. Am Fam Physician 1994;50: 819-23,825-6.